Insys Therapeutics (INSY) Inactive 10-Q2018 Q1 Quarterly report

Filed: 10 May 18, 5:03pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Good

New words: AG, Alec, American, Angelo, assert, asserting, BDO, bioequivalence, Bobby, book, branded, Breitenbach, Brian, broadly, Bulletin, Burlakoff, children, citizen, CODM, Concentration, conclusion, confinement, Congressional, constrained, Conversely, Cosmetic, covenant, customary, dealing, defect, delivered, Departure, destruction, detail, Diana, disaggregated, disagreement, discovery, donut, driver, Edward, eligibility, estoppel, Executor, Exhibit, expedient, faith, fasted, FDC, Friday, friend, gap, good, Hampton, handling, harm, Heir, herewith, hole, Holper, home, immaterial, implied, IMS, indemnity, Indiana, IQVIA, issuance, Jerrold, Jordan, Leavensworth, Lisa, LLP, Louisiana, macro, Magistrate, Mencucci, mention, mentioned, Mexico, Michelle, migration, Mississippi, Monmouth, Morgan, Munson, Native, Nevada, nonrecurring, Oklahoma, petition, preclude, preemption, Proposal, proposed, provisional, proxy, ratified, Ray, Recommendation, recommending, Regional, registered, registrant, relevant, Rosenberg, satisfaction, Scott, seasonal, shortly, Show, Statue, strict, sue, Sunshine, Supreme, survival, survivor, switched, Tambi, Technical, Tennessee, text, Thursday, tooling, trend, Utah, venue, Virginia, vivo, voluntarily, voting, waiver, Wake, West, widespread, Witham, worsen, yearly

Removed: accuracy, advertising, agent, alleging, analyzing, annum, appealed, applying, appraisal, arrangement, assessment, assignment, assured, await, awarding, cancelled, ceiling, Clara, clarification, clarified, compounded, consultant, coordinate, creating, criterion, deduction, discrete, display, disposal, documentation, employment, enhanced, exercised, exist, expended, fairly, floor, found, founder, fractional, fraudulent, generate, group, hydrocodone, impacted, informed, initially, initiated, mandatory, medication, mitigate, modestly, monitor, negatively, nuisance, obsolescence, Orange, overdose, oxycodone, pace, passed, payable, pediatric, persuasive, PK, predictable, preservation, profession, prospectively, rapid, readily, recover, reflecting, remediation, rendered, replacement, repurchase, requisite, rescind, rescission, rescissory, reserve, retained, retrospectively, reverse, revised, rigor, Santa, Simplifying, sized, split, statutory, study, successor, terminated, timely, tolling, tone, top, treated, vested, vi, volatility, Wednesday, windfall, withheld

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

INSY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Insys Therapeutics, Inc. (the “Company”), for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, Saeed Motahari, principal executive officer of the Company, and Andrew G. Long, principal financial officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Saeed Motahari
	Saeed Motahari
	President and Chief Executive Officer
	(Principal Executive Officer)

Dated May 10, 2018

By:	/s/ Andrew G. Long
	Andrew G. Long
	Chief Financial Officer
	(Principal Financial Officer)

Dated May 10, 2018